Trial Profile
A Randomized, Double-blind, Multi-center, Standard Therapy Based, Placebo parallel Controlled Phase II Clinical Trial to Evaluate the Effect of Recombinant Human Neuregulin-1 for Injection on the Survival
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2016
Price :
$35
*
At a glance
- Drugs Recombinant human neuregulin 1-beta (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
- 23 May 2013 Results published in a Zensun Sci & Tech media release.
- 21 May 2012 Planned end date (18 Dec 2011) added as reported by Chinese Clinical Trial Register.
- 05 Jan 2012 New trial record